What To Know
- “In the realm of early detection of AL, there is currently no technology that offers clinicians insights on the state of a patient's internal tissue healing following resection surgery in the GI,” explained Erez Shor, PhD.
- Exero Medical today announced that it has been granted FDA Breakthrough Designation, a status reserved for medical devices that provide more effective treatment or diagnosis of potentially life-threatening or irreversible conditions or diseases.
December 15, 2020
Exero Medical, is a developer of a wireless system for early detection of anastomotic leaks (AL) following gastrointestinal (GI) surgery.
Exero Medical today announced that it has been granted FDA Breakthrough Designation, a status reserved for medical devices that provide more effective treatment or diagnosis of potentially life-threatening or irreversible conditions or diseases.
To achieve this status, Exero Medical demonstrated that its smart sensor for the early detection of potentially lethal AL following GI surgery represents a breakthrough that may demonstrate substantial improvement over any available solution.
“In the realm of early detection of AL, there is currently no technology that offers clinicians insights on the state of a patient’s internal tissue healing following resection surgery in the GI,” explained Erez Shor, PhD., CEO of Exero Medical. “The time needed today to obtain definitive diagnosis of a leak often puts the patient in a critical state of health. Alternatively, some surgeons order invasive interventions as a precautionary step, putting patients through often-unnecessary additional procedures. Our system is designed to provide clinicians the needed data on tissue healing well before a patient reaches a catastrophic situation, enabling more precise and effective intervention, minimizing complications and potentially saving lives.”
To confirm that Exero’s smart sensor may provide effective early diagnosis of AL, the FDA scrutinized the company’s pre-clinical data from its animal studies as well as clinical data collected in the first in-human feasibility trial conducted at Rabin Medical Center.
“We are thrilled to work with the FDA to optimize our regulatory process. I expect the rapid interaction with FDA will reduce our time to market,” added Shor.”
“Erez and his team have developed a life-saving technology using a multi-disciplinary approach to medical device development that will have a significant impact on the GI surgical market,” said Shai Policker, CEO of MEDX Xelerator. “Achieving the FDA’s Breakthrough Designation at this stage attests to the quality of their initial R&D and the urgent need for this technology to reach the hands of clinicians.”
Exero Medical is a portfolio company of MEDX Xelerator, a medical device and digital health focused incubator based in Israel, formed as a partnership between Boston Scientific, MEDX Ventures and Sheba Medical Center.
